Skurtveit Svetlana, Hjellvik Vidar, Sakshaug Solveig, Borchgrevink Petter C, Larsen Børge Myrlund, Clausen Thomas, Skovlund Eva, Heggen Emilie Elise, Handal Marte
Tidsskr Nor Laegeforen. 2020 Oct 19;140(15). doi: 10.4045/tidsskr.20.0153. Print 2020 Oct 27.
In 2008 the reimbursable prescription scheme was amended so that patients with severe, chronic pain could be prescribed opioids on reimbursable prescription. The purpose of this study was to investigate the prescribing of opioids on reimbursable prescription, the proportion of patients who started opioid treatment on reimbursable prescription who became long-term users, and the number of patients in 2018 who received higher dosages than the reimbursable prescription scheme permits.
Data were retrieved from the Norwegian Prescription Registry. Persons aged 18 or over who were dispensed at least one opioid on reimbursable prescription for severe, chronic pain in the period 2008-2018, were included.
The number of patients who were prescribed opioids on reimbursable prescription increased during the study period, and in 2018 the number was 17 383. Of these, 331 (1.9 %) were prescribed more than 300 mg oral morphine equivalents per day. After nine years, 48 % of the patients who started with opioids in 2009 were still being prescribed opioids on reimbursable prescription.
A high proportion of patients with severe, chronic pain who started with opioids on reimbursable prescription became long-term users. A number of patients received higher dosages than are recommended.
2008年，可报销处方计划进行了修订，以便患有严重慢性疼痛的患者可以通过可报销处方开具阿片类药物。本研究的目的是调查可报销处方中阿片类药物的开具情况、开始使用可报销处方阿片类药物治疗的患者成为长期使用者的比例，以及2018年接受高于可报销处方计划允许剂量的患者数量。
数据取自挪威处方登记处。纳入了2008年至2018年期间年龄在18岁及以上、因严重慢性疼痛通过可报销处方至少配给过一次阿片类药物的人员。
在研究期间，通过可报销处方开具阿片类药物的患者数量有所增加，2018年这一数字为17383人。其中，331人（1.9%）每天开具的口服吗啡当量超过300毫克。九年后，2009年开始使用阿片类药物的患者中有48%仍通过可报销处方开具阿片类药物。
许多因严重慢性疼痛开始通过可报销处方使用阿片类药物的患者成为了长期使用者。一些患者接受的剂量高于推荐剂量。
